Literature DB >> 2327235

Nervous system manifestations in Sjögren's syndrome.

A Hietaharju1, U Yli-Kerttula, V Häkkinen, H Frey.   

Abstract

Central and peripheral manifestations of the nervous system were evaluated in 48 Sjögren's syndrome patients. Fifty-six percent of the patients had neurological disturbances. The most common manifestations were entrapment neuropathies (19%) and polyneuropathy (15%). Electrophysiological tests gave further evidence of subclinical nervous system involvement in Sjögren's syndrome: electroencephalography (EEG) was abnormal in 48%, and visual evoked potentials (VEP) in 12% of patients tested. To find possible neuropsychiatric abnormalities, the Minnesota Multiphasic Personality Inventory was applied, and 33/43 patients were found to have psychiatric symptoms. The most frequent were depressive symptoms. In 44% of the patients there was additional evidence of extraglandular involvement or autoimmune disorders. No correlation could be found between the groups of patients with or without neurological disturbances in relation to simultaneous occurrence of associated disorders. It is suggested that nervous system involvement in Sjögren's syndrome reflects the pathogenetic consequences of Sjögren's syndrome alone, and not those of associated autoimmune diseases of extraglandular disorders.

Entities:  

Mesh:

Year:  1990        PMID: 2327235     DOI: 10.1111/j.1600-0404.1990.tb00951.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  16 in total

Review 1.  CNS involvement in primary Sjögren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach.

Authors:  M Govoni; M Padovan; N Rizzo; F Trotta
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Central nervous system involvement in Sjogren's syndrome.

Authors:  F C Soliotis; C P Mavragani; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

Review 3.  [Differential diagnosis of chronic inflammatory diseases of the central nervous system. Cerebrospinal fluid diagnosis and immunological parameters].

Authors:  D Reske; H-F Petereit
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

4.  Systemic inflammatory disorders in patients admitted for aseptic meningitis.

Authors:  Marine Boudot de la Motte; Rachid Abbas; Fanny Jouan; Damien van Gysel; Marie Paule Chauveheid; Thomas Papo; Karim Sacre
Journal:  Clin Med (Lond)       Date:  2018-03       Impact factor: 2.659

5.  Unusual presentation of Sjögren's syndrome.

Authors:  Aicha Bouraoui; Syed Farhan Bari; Julian Nash; Kenneth Dawson
Journal:  BMJ Case Rep       Date:  2014-11-20

6.  Nervous system disease, immunological features, and HLA phenotype in Sjögren's syndrome.

Authors:  A Hietaharju; M Korpela; J Ilonen; H Frey
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

7.  Autonomic cardiovascular neuropathy in primary Sjögren's syndrome.

Authors:  A P Andonopoulos; C Ballas
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

8.  Abnormal regional cerebral blood flow on 99mTc ECD brain SPECT in patients with primary Sjögren's syndrome and normal findings on brain magnetic resonance imaging.

Authors:  C P Chang; Y C Shiau; J J Wang; S T Ho; A Kao
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

9.  Detecting abnormal regional cerebral blood flow in patients with primary Sjögren's syndrome by technetium-99m ethyl cysteinate dimer single photon emission computed tomography of the brain--a preliminary report.

Authors:  W S Huang; P Y Chiu; A Kao; C H Tsai; C C Lee
Journal:  Rheumatol Int       Date:  2003-02-18       Impact factor: 2.631

10.  Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States.

Authors:  Barbara Segal; Simon J Bowman; Philip C Fox; Frederick B Vivino; Nandita Murukutla; Jeff Brodscholl; Sarika Ogale; Lachy McLean
Journal:  Health Qual Life Outcomes       Date:  2009-05-27       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.